CASTLE BIOSCIENCES INC (CSTL) Stock Price, Forecast & Analysis
NASDAQ:CSTL • US14843C1053
CSTL Key Statistics, Chart & Performance
The current stock price of CSTL is 33.15 USD. In the past month the price decreased by -18.65%. In the past year, price increased by 21.34%.
CSTL Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CSTL. When comparing the yearly performance of all stocks, CSTL turns out to be only a medium performer in the overall market: it outperformed 66.01% of all stocks.
CSTL Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to CSTL. While CSTL has a great health rating, there are worries on its profitability.
CSTL Financial Highlights
Over the last trailing twelve months CSTL reported a non-GAAP Earnings per Share(EPS) of 0.26. The EPS increased by 30% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.17% | ||
| ROE | -2.62% | ||
| Debt/Equity | 0.02 |
CSTL Forecast & Estimates
14 analysts have analysed CSTL and the average price target is 45.75 USD. This implies a price increase of 38.02% is expected in the next year compared to the current price of 33.15.
For the next year, analysts expect an EPS growth of -271.62% and a revenue growth 2.27% for CSTL
CSTL Ownership
CSTL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 10.84 | 98.927B | ||
| CI | THE CIGNA GROUP | 9.32 | 75.774B | ||
| LH | LABCORP HOLDINGS INC | 15.69 | 23.055B | ||
| DGX | QUEST DIAGNOSTICS INC | 19.68 | 23.011B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 92.25 | 22.794B | ||
| GH | GUARDANT HEALTH INC | N/A | 13.24B | ||
| DVA | DAVITA INC | 11.26 | 10.28B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 28.36 | 6.815B | ||
| CHE | CHEMED CORP | 18.44 | 6.57B | ||
| OPCH | OPTION CARE HEALTH INC | 18.58 | 5.465B |
Related stock screener links
View all stocks in the Health Care Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CSTL
Company Profile
Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The company is headquartered in Friendswood, Texas and currently employs 761 full-time employees. The company went IPO on 2019-07-25. The firm offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. The company also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). The company also focused on chronic acid reflux related diseases, including esophageal cancer.
Company Info
CASTLE BIOSCIENCES INC
1500 W. Parkwood Ave., Suite 401
Friendswood TEXAS 77546 US
CEO: Derek J. Maetzold
Employees: 761
Phone: 18667889007
CASTLE BIOSCIENCES INC / CSTL FAQ
What does CSTL do?
Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The company is headquartered in Friendswood, Texas and currently employs 761 full-time employees. The company went IPO on 2019-07-25. The firm offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. The company also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). The company also focused on chronic acid reflux related diseases, including esophageal cancer.
Can you provide the latest stock price for CASTLE BIOSCIENCES INC?
The current stock price of CSTL is 33.15 USD. The price increased by 3.92% in the last trading session.
What is the dividend status of CASTLE BIOSCIENCES INC?
CSTL does not pay a dividend.
What is the ChartMill rating of CASTLE BIOSCIENCES INC stock?
CSTL has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Is CASTLE BIOSCIENCES INC (CSTL) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CSTL.
What is the outstanding short interest for CASTLE BIOSCIENCES INC?
The outstanding short interest for CASTLE BIOSCIENCES INC (CSTL) is 5.5% of its float.